Is Hims & Hers Health, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Hims & Hers Health, Inc. moved from very expensive to expensive, indicating a shift towards a less favorable valuation. The company appears to be overvalued based on its current metrics. Key ratios include a P/E ratio of 74, an EV to EBITDA of 89.10, and a Price to Book Value of 22.96, which are significantly higher than many peers in the industry.
In comparison, Guardant Health, Inc. has a P/E of -17.69, while Addus HomeCare Corp. shows a more reasonable P/E of 22.05, highlighting the relative overvaluation of Hims & Hers. Despite strong returns of 130.89% over the past year compared to the S&P 500's 14.08%, the elevated valuation ratios suggest that the stock may not sustain its current price levels in the long term.